论文部分内容阅读
目的:探讨重组人IL-11治疗对放化疗鼻咽癌患者预后的影响。方法:将78例鼻咽癌患者按随机信封抽签原则分为观察组与对照组各39例,对照组给予常规放化疗,观察组在对照组治疗的基础上给予重组人IL-11治疗,两组都完成2个周期治疗。结果:观察组总有效率(87.2%)高于对照组(59.0%),差异有统计学意义(P<0.05)。观察组在治疗期间放射性口腔黏膜炎0级14例,Ⅰ级6例,Ⅱ级14例,Ⅲ级5例;对照组0级28例,Ⅰ级5例,Ⅱ级4例,Ⅲ级2例,总体比较差异有统计学意义(P<0.05)。治疗后观察组与对照组的血清CRP分别为(5.32±1.92)mg/L和(12.44±2.48)mg/L,明显低于治疗前的(24.59±3.14)mg/L和(24.12±2.87)mg/L(均P<0.05);治疗后,观察组血清CRP明显低于对照组(P<0.05)。治疗后观察组与对照组的疼痛评分明显低于治疗前(P<0.05);治疗后,观察组疼痛评分低于对照组(P<0.05)。结论:重组人IL-11治疗在放化疗鼻咽癌患者中的应用能促进血清CRP表达下降,缓解疼痛,减轻放射性口腔黏膜炎,从而提高预后疗效。
Objective: To investigate the effect of recombinant human IL-11 on the prognosis of patients with nasopharyngeal carcinoma after radiotherapy and chemotherapy. Methods: 78 patients with nasopharyngeal carcinoma were randomly divided into observation group and control group according to the principle of random ensemble. The control group received conventional radiotherapy and chemotherapy. The observation group received recombinant human IL-11 treatment on the basis of the control group. The group completed 2 cycles of treatment. Results: The total effective rate (87.2%) in the observation group was higher than that in the control group (59.0%), the difference was statistically significant (P <0.05). In the observation group, there were 14 cases of grade 0, 6 cases of grade Ⅰ, 14 cases of grade Ⅱ and 5 cases of grade Ⅲ. There were 28 cases of grade 0 in control group, 5 cases of grade Ⅰ, 4 cases of grade Ⅱ and 2 cases of grade Ⅲ , The overall difference was statistically significant (P <0.05). After treatment, the serum CRP in the observation group and the control group were (5.32 ± 1.92) mg / L and (12.44 ± 2.48) mg / L respectively, which were significantly lower than those before treatment (24.59 ± 3.14) mg / L and (24.12 ± 2.87) mg / L (all P <0.05). After treatment, serum CRP in the observation group was significantly lower than that in the control group (P <0.05). After treatment, the pain scores of observation group and control group were significantly lower than those before treatment (P <0.05). After treatment, pain scores of observation group were lower than those of control group (P <0.05). Conclusion: The application of recombinant human IL-11 in the treatment of nasopharyngeal carcinoma patients with radiotherapy and chemotherapy can promote the decline of serum CRP expression, relieve pain and reduce radiation oral mucositis, thereby improving the prognosis.